TXG vs Peers Stock Comparison

10x Genomics Prices as of Oct 26, 2026 Peers: Industry group
TXG 10x Genomics, Inc.
$72.96 -14.9% 1M +429.8% 1Y
Market cap
$10.15B
P/E
–
Revenue (TTM)
$616.91M
Div. yield
–
Life Sciences Tools Healthcare

Percentile Scorecard

TXG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTXG
Valuation 43 #130 of 228
Growth 66 #76 of 221
Profitability 63 #77 of 208
Financial Health 68 #78 of 239
Shareholder Returns 67 #46 of 137
Overall 61
  • TXG ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTXGSPY
1 month -14.9% -0.8%
3 months +58.9% +3.5%
6 months +227.5% +7.0%
Year to date +347.3% +12.2%
1 year +429.8% +13.0%
3 years +100.4% +86.3%
3 years, per year +26.1% +23.1%
5 years -54.1% +68.6%
5 years, per year -14.4% +11.0%

Risk

MeasureTXGSPY
Volatility, 1Y 73.8% 12.7%
Downside volatility, 1Y 66.1% 12.7%
Beta vs S&P 500, 1Y 2.21 1.00
Return / volatility, 1Y 5.82 1.02
Max drawdown, 5Y -96.1% -25.4%
From 52-week high -25.4% -1.8%
52-week high $97.74 $779.14
52-week low $12.44 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTXG
P/E now vs peer median -126.2xmedian 30.6x
P/S now vs peer median 15.4xmedian 3.0x
EV/EBITDA now vs peer median -212.9xmedian 17.5x
P/FCF now vs peer median 78.3xmedian 23.3x
P/B now vs peer median 11.5xmedian 2.4x
PEG now vs peer median -4.70median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTXG
Revenue $616.91M
Gross profit $432.03M
Operating income -$88.38M
Net income -$75.13M
Free cash flow $121.44M
R&D $226.80M
EPS (diluted) $-0.58
Shares (diluted) 129.98M
Enterprise value $9.95B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTXG
P/E -126.2x
P/FCF 78.3x
P/Operating cash flow 74.8x
P/S 15.4x
P/B 11.5x
P/Tangible book 12.4x
EV/EBITDA -212.9x
EV/EBIT -107.0x
EV/Revenue 15.3x
EV/FCF 77.9x
EV/Operating cash flow 74.4x
PEG (3Y EPS CAGR) -4.70

Growth

14 metrics
MetricTXG
Revenue growth (1Y) -4.3%
Revenue CAGR (3Y) 2.8%
Gross profit growth (1Y) -3.5%
Gross profit CAGR (3Y) 1.1%
Operating income growth (1Y) 12.1%
Operating income CAGR (3Y) 20.9%
Net income growth (1Y) 11.2%
Net income CAGR (3Y) 24.2%
EPS growth (1Y) 14.9%
EPS CAGR (3Y) 26.8%
Operating cash flow growth (1Y) 89.8%
Operating cash flow CAGR (3Y) 135.5%
Free cash flow growth (1Y) 113.5%
Free cash flow CAGR (3Y) 44.7%

Profitability

14 metrics
MetricTXG
Gross margin 70.0%
EBITDA margin -7.2%
Operating margin -14.3%
Pretax margin -12.1%
Net margin -12.2%
FCF margin 19.7%
Operating cash flow margin 20.6%
Return on equity -9.2%
Return on assets -7.3%
Return on invested capital –
Return on capital employed -9.8%
Asset turnover 0.6x
Cash conversion (OCF / net income) -1.7x
Stock comp / revenue 16.0%

Financial Health

11 metrics
MetricTXG
Debt / assets –
Debt / equity –
Net debt / EBITDA –
Debt / FCF –
Liabilities / assets 19.9%
Equity / assets 80.1%
Interest coverage –
Current ratio 5.7x
Quick ratio 0.8x
Cash ratio 0.4x
Altman Z-score 26.75

Shareholder Returns

7 metrics
MetricTXG
Dividend yield –
Net buyback yield -0.1%
Shareholder yield -0.1%
Payout ratio (earnings) –
Payout ratio (FCF) –
Dividend growth (1Y) –
Dividend CAGR (3Y) –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTXG
EPS, next fiscal year $-0.79FY2026
Revenue, next fiscal year $580.42MFY2026
Revenue growth, next FY -9.7%FY2026
Revenue growth, the year after +24.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTXG
Held by institutions 100.0%
Institutions holding 389
Change in shares held, QoQ +2.4%
Institutions buying 197
Institutions selling 137
Buyers to sellers 1.44

Add a Peer

Largest companies in the same industry

Related Comparisons

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.